Cpwm LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 737 shares of the life sciences company’s stock, valued at approximately $271,000.
A number of other hedge funds also recently bought and sold shares of ILMN. Wetherby Asset Management Inc. increased its position in Illumina by 7.1% during the 3rd quarter. Wetherby Asset Management Inc. now owns 2,259 shares of the life sciences company’s stock valued at $829,000 after purchasing an additional 149 shares during the period. Cadence Capital Management LLC increased its position in Illumina by 3.6% during the 2nd quarter. Cadence Capital Management LLC now owns 4,702 shares of the life sciences company’s stock valued at $1,313,000 after purchasing an additional 162 shares during the period. Stone Ridge Asset Management LLC increased its position in Illumina by 7.1% during the 3rd quarter. Stone Ridge Asset Management LLC now owns 2,557 shares of the life sciences company’s stock valued at $939,000 after purchasing an additional 169 shares during the period. Kingfisher Capital LLC increased its position in Illumina by 2.1% during the 3rd quarter. Kingfisher Capital LLC now owns 8,653 shares of the life sciences company’s stock valued at $3,176,000 after purchasing an additional 176 shares during the period. Finally, Puzo Michael J increased its position in Illumina by 1.8% during the 3rd quarter. Puzo Michael J now owns 10,303 shares of the life sciences company’s stock valued at $3,782,000 after purchasing an additional 180 shares during the period. 88.91% of the stock is currently owned by institutional investors.
A number of research firms have commented on ILMN. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Barclays raised their target price on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research report on Wednesday, October 24th. BidaskClub raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 1st. Deutsche Bank raised their target price on shares of Illumina to $350.00 and gave the company a “buy” rating in a research report on Friday, October 12th. Finally, Argus set a $372.00 target price on shares of Illumina and gave the company a “buy” rating in a research report on Friday, August 10th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Illumina currently has a consensus rating of “Buy” and a consensus target price of $330.94.
Shares of Illumina stock opened at $321.41 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.24 and a debt-to-equity ratio of 0.24. Illumina, Inc. has a 52-week low of $207.51 and a 52-week high of $372.61. The company has a market capitalization of $49.15 billion, a PE ratio of 57.25, a PEG ratio of 2.48 and a beta of 1.09.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.26. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The firm had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. During the same quarter in the previous year, the firm earned $1.11 EPS. The company’s quarterly revenue was up 19.5% compared to the same quarter last year. On average, equities research analysts expect that Illumina, Inc. will post 5.75 earnings per share for the current fiscal year.
In related news, Director Robert S. Epstein sold 1,346 shares of Illumina stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $369.15, for a total value of $496,875.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $351.66, for a total transaction of $1,160,478.00. Following the completion of the sale, the director now owns 392,204 shares of the company’s stock, valued at $137,922,458.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,082 shares of company stock worth $23,398,609. Insiders own 0.54% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/12/08/cpwm-llc-purchases-new-position-in-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: What is Cost of Debt?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.